Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Authors
Keywords
-
Journal
Neurotherapeutics
Volume 14, Issue 4, Pages 859-873
Publisher
Springer Nature
Online
2017-08-16
DOI
10.1007/s13311-017-0565-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases
- (2017) Sinead O'Sullivan et al. NEUROPHARMACOLOGY
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
- (2016) F L Scott et al. BRITISH JOURNAL OF PHARMACOLOGY
- From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?
- (2016) Frédéric J Zécri CURRENT OPINION IN CHEMICAL BIOLOGY
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
- (2016) Hsing-Chuan Tsai et al. DRUGS
- Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis
- (2016) Douglas R Jeffery et al. Expert Review of Neurotherapeutics
- The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures
- (2016) Catherine O’Sullivan et al. Journal of Neuroinflammation
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
- (2016) Marine Boudot de la Motte et al. Multiple Sclerosis Journal
- Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis
- (2016) Douglas R Jeffery et al. Expert Review of Neurotherapeutics
- Perspectives on Safety and Efficacy—The BOLD Phase 2 Extension Study of Siponimod in Relapsing-Remitting Multiple Sclerosis
- (2016) Edward R. Hammond JAMA Neurology
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
- (2016) Ludwig Kappos et al. JAMA Neurology
- Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
- (2016) Marine Boudot de la Motte et al. Multiple Sclerosis Journal
- Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
- (2015) Laura Ordoñez-Boschetti et al. ADVANCES IN THERAPY
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
- (2015) Jeffrey A Cohen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- 36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice
- (2015) T Ziemssen et al. VALUE IN HEALTH
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Modulators of the Sphingosine 1-phosphate receptor 1
- (2013) Mariangela Urbano et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study
- (2013) Patrick Brossard et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
- (2013) Ralf Gold et al. JOURNAL OF NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
- (2013) Shifeng Pan et al. ACS Medicinal Chemistry Letters
- Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects
- (2012) Eric Legangneux et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate
- (2012) P Gergely et al. BRITISH JOURNAL OF PHARMACOLOGY
- Early tolerability and safety of fingolimod in clinical practice
- (2012) Daniel Ontaneda et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Sudden unexpected death on fingolimod
- (2012) JW Lindsey et al. Multiple Sclerosis Journal
- Fingolimod-associated macular edema: Incidence, detection, and management
- (2012) N. Jain et al. NEUROLOGY
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Delayed fingolimod-associated asystole
- (2011) Patricio S Espinosa et al. Multiple Sclerosis Journal
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- Fingolimod is a potential novel therapy for multiple sclerosis
- (2010) Orhan Aktas et al. Nature Reviews Neurology
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now